Scientists can finally hunt down a harmful kind of human T cell. Immune cells called ex-T regulatory cells (exTregs) tend to be rare in the body and, so far, impossible to detect in human samples.

They investigated markers associated with the activation and residency of regulatory T cells. They assessed vascular-exposed regulatory T populations using antibodies against the cluster of ...

First, they used flow cytometry to hunt for cells within the dura mater expressing the telltale combination of Treg markers—CD4 and FoxP3. At just 125 cells per mouse, ... This highly novel study ...

They found that in addition to reduced expression of CD127, the product of IL7R, these cells expressed CD45RO, a marker that identifies memory T cells. The researchers also found these CD127 - CD45RO ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

Celiac disease is also a good candidate for regulatory T-cell therapy because in more than 90% of patients it is caused by a genetic variant called HLA-DQ2.5, Muller added.

One strategy is to bolster regulatory T cells. T-regs keep their killer cousins in check by secreting a portion of anti-inflammatory cytokines. Few T-regs reside in the brain, but a recent study did ...

Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC.

HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

A recent study by a team led by Professor Shin Kaneko successfully induced regulatory T cell ... With this marker, treating iCD4 + T cells with AMRT resulted in similarly high FOXP3 CNS2 TSDR ...

Actileucel uses activated regulatory T cells from a second donor, who does not need to match the patient’s tissue markers, to control or prevent GvHD. Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx , ...